Purpose Up to 47% of patients with localized prostate cancer ( PCa) treated with radiotherapy (EBRT) eventually develop local recurrence. To date, no clear consensus exists on optimal management. A growing body of interest supports the use of stereotaxic re-irradiation (rSBRT), with promising oncological outcomes and low toxicity profile. We collected a singlecenter case series of locally recurrent PCa who underwent re-irradiation after a previous course of postoperative or definitive radiotherapy.Methods and materials Data from 101 patients treated at our institution for locally recurrent PCa from June 2012 to June 2021 were retrospectively collected. Patients underwent rSBRT with CyberKnife system (Accuray Inc., Sunnyvale, CA, USA), delivered to intraprostatic or macroscopic recurrences within the prostate bed, for a total dose of 30 Gy in 5 fractions.Results All patients received prior EBRT. The median EQD2 total dose was 75.0 Gy (range, 60-80 Gy). Thirty-two (32%) patients were receiving androgen deprivation therapy (ADT) after prior biochemical recurrence. After a median followup of 57.8 months, BR occurred in 55 patients (54.5%), with a median BR-free survival (BRFS) of 40.4 months (95% C.I. 34.3-58.3). Thirty-two patients (31.7%) developed metastatic disease, with a median metastasis-free survival (MFS) not reached. PSA >= 2.5 ng/ml and ADT were associated with worst BRFS (26.06 vs. 39.3 months, p = 0.03 and 22.7 vs. 27 months, p = 0.01, respectively). Castration-resistant status and ADT were found to be predictive of worst MFS (34.1 vs. 50.5 months, p = 0.02 and 33.5 vs. 53.1 months, p = 0.002, respectively). Concomitant ADT was confirmed as an independent factor for MFS (HR 4.8, 95% CI 1.5-10.6, p = 0.007). No grade > /2 adverse were recorded.Conclusions After almost 5 years of follow-up, with a median BRFS of 40.4 months and no grade = 2 AEs, CyberknifeR rSBRT proved effective and safe in a cohort of 101 patients affected by locally recurrent PCa.

Stereotactic reirradiation with CyberknifeR for locally recurrent prostate cancer, long-term toxicity and clinical outcomes from a monocentric cohort / Francolini, Giulio; Carnevale, Maria Grazia; Di Cataldo, Vanessa; Loi, Mauro; Detti, Beatrice; Orsatti, Carolina; Caprara, Luisa; Bertini, Niccolò; Lorenzetti, Victoria; Olmetto, Emanuela; Becherini, Carlotta; Visani, Luca; Salvestrini, Viola; Simontacchi, Gabriele; Greto, Daniela; Bonomo, Pierluigi; Doro, Raffaela; Masi, Laura; Desideri, Isacco; Meattini, Icro; Serni, Sergio; Livi, Lorenzo. - In: LA RADIOLOGIA MEDICA. - ISSN 1826-6983. - ELETTRONICO. - (2023), pp. 0-0. [10.1007/s11547-023-01721-7]

Stereotactic reirradiation with CyberknifeR for locally recurrent prostate cancer, long-term toxicity and clinical outcomes from a monocentric cohort

Francolini, Giulio;Carnevale, Maria Grazia;Di Cataldo, Vanessa;Loi, Mauro;Detti, Beatrice;Orsatti, Carolina;Caprara, Luisa;Lorenzetti, Victoria;Olmetto, Emanuela;Becherini, Carlotta;Visani, Luca;Salvestrini, Viola;Simontacchi, Gabriele;Greto, Daniela;Bonomo, Pierluigi;Desideri, Isacco;Meattini, Icro;Serni, Sergio;Livi, Lorenzo
2023

Abstract

Purpose Up to 47% of patients with localized prostate cancer ( PCa) treated with radiotherapy (EBRT) eventually develop local recurrence. To date, no clear consensus exists on optimal management. A growing body of interest supports the use of stereotaxic re-irradiation (rSBRT), with promising oncological outcomes and low toxicity profile. We collected a singlecenter case series of locally recurrent PCa who underwent re-irradiation after a previous course of postoperative or definitive radiotherapy.Methods and materials Data from 101 patients treated at our institution for locally recurrent PCa from June 2012 to June 2021 were retrospectively collected. Patients underwent rSBRT with CyberKnife system (Accuray Inc., Sunnyvale, CA, USA), delivered to intraprostatic or macroscopic recurrences within the prostate bed, for a total dose of 30 Gy in 5 fractions.Results All patients received prior EBRT. The median EQD2 total dose was 75.0 Gy (range, 60-80 Gy). Thirty-two (32%) patients were receiving androgen deprivation therapy (ADT) after prior biochemical recurrence. After a median followup of 57.8 months, BR occurred in 55 patients (54.5%), with a median BR-free survival (BRFS) of 40.4 months (95% C.I. 34.3-58.3). Thirty-two patients (31.7%) developed metastatic disease, with a median metastasis-free survival (MFS) not reached. PSA >= 2.5 ng/ml and ADT were associated with worst BRFS (26.06 vs. 39.3 months, p = 0.03 and 22.7 vs. 27 months, p = 0.01, respectively). Castration-resistant status and ADT were found to be predictive of worst MFS (34.1 vs. 50.5 months, p = 0.02 and 33.5 vs. 53.1 months, p = 0.002, respectively). Concomitant ADT was confirmed as an independent factor for MFS (HR 4.8, 95% CI 1.5-10.6, p = 0.007). No grade > /2 adverse were recorded.Conclusions After almost 5 years of follow-up, with a median BRFS of 40.4 months and no grade = 2 AEs, CyberknifeR rSBRT proved effective and safe in a cohort of 101 patients affected by locally recurrent PCa.
2023
0
0
Francolini, Giulio; Carnevale, Maria Grazia; Di Cataldo, Vanessa; Loi, Mauro; Detti, Beatrice; Orsatti, Carolina; Caprara, Luisa; Bertini, Niccolò; Lorenzetti, Victoria; Olmetto, Emanuela; Becherini, Carlotta; Visani, Luca; Salvestrini, Viola; Simontacchi, Gabriele; Greto, Daniela; Bonomo, Pierluigi; Doro, Raffaela; Masi, Laura; Desideri, Isacco; Meattini, Icro; Serni, Sergio; Livi, Lorenzo
File in questo prodotto:
File Dimensione Formato  
2023_Francolini_Rad Med_Reirradiation CK prostate.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: DRM non definito
Dimensione 938.32 kB
Formato Adobe PDF
938.32 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1343491
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact